Merck KGaA, Darmstadt, Germany, Successfully Divests Allergopharma
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today completed the divestment of Allergopharma to Dermapharm Holding SE (“Dermapharm”) following regulatory approval and the satisfaction of other customary closing conditions. With the successful transaction closing, the Healthcare business sector will further sharpen its focus on the development of innovative medicines for difficult-to-treat diseases.
The allergy business of Merck KGaA, Darmstadt, Germany, in Europe was transferred to Dermapharm on March 31. The transfer of the Allergopharma business in China is planned for the second half of 2020. The two parties have agreed not to disclose the purchase price.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Merck KGaA, Darmstadt, Germany today announced that updated data from the ongoing, single-arm Phase II VISION study evaluating tepotinib* were published.